The hand-foot-syndrome associated with medical tumor therapy - classification and management

被引：123

作者：

Degen, Annette ^{[1
]}

Alter, Mareike ^{[1
]}

Schenck, Florian ^{[1
]}

Satzger, Imke ^{[1
]}

Voelker, Bernward ^{[1
]}

Kapp, Alexander ^{[1
]}

Gutzmer, Ralf ^{[1
]}

机构：

[1] Hannover Med Sch, Skin Canc Ctr Hannover HTZH, Clin & Polyclin Dermatol & Allergy, Hannover, Germany

来源：

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2010年 / 8卷 / 09期

关键词：

medical tumor therapy; hand-foot-syndrome; palmoplantar; erythrodysesthesia; PALMAR-PLANTAR ERYTHRODYSESTHESIA; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE-II TRIAL; KINASE INHIBITORS SORAFENIB; METASTATIC BREAST-CANCER; SKIN REACTION; ACRAL ERYTHEMA; ERYTHRODYSAESTHESIA SYNDROME; CUTANEOUS TOXICITY; PYRIDOXINE THERAPY;

D O I：

10.1111/j.1610-0387.2010.07449.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P>The hand-foot-syndrome (HFS, palmoplantar erythrodysesthesia, chemotherapy-associated acral erythema) is characterized by painful predominantly palmo-plantar lesions. The association with different chemotherapeutic agents has been known for over 20 years. More recently, HFS has been reported in association with regimens using targeted agents, in particular the multikinase inhibitors (MKI) sorafenib and sunitinib. The HFS associated with MKI has a different distribution and clinical appearance than the traditional disorder. In this review, similarities and differences between chemotherapy- and MKI-associated HFS are discussed and current recommendations for their prophylaxis and management are summarized.

引用

页码：652 / 661

页数：10

共 59 条

[51]

TROUSSARD X, 1993, BONE MARROW TRANSPL, V11, P501

[52]

Vail DM, 1998, CLIN CANCER RES, V4, P1567

[53] Chemotherapy-induced eccrine squamous syringometaplasia - A distinctive eruption in patients receiving hematopoietic progenitor cells [J].